GW-788,388

GW-788,388
Identifiers
IUPAC name
  • 4-(4-(3-(pyridin-2-yl)-1H-pyrazol-4-yl)pyridin-2-yl)-N-(tetrahydro-2H-pyran-4-yl)benzamide
CAS Number
PubChem CID
Chemical and physical data
FormulaC25H23N5O2
Molar mass425.492 g·mol−1
3D model (JSmol)
SMILES
  • C1COCCC1NC(=O)C2=CC=C(C=C2)C3=NC=CC(=C3)C4=C(NN=C4)C5=CC=CC=N5
InChI
  • InChI=1S/C25H23N5O2/c31-25(29-20-9-13-32-14-10-20)18-6-4-17(5-7-18)23-15-19(8-12-27-23)21-16-28-30-24(21)22-3-1-2-11-26-22/h1-8,11-12,15-16,20H,9-10,13-14H2,(H,28,30)(H,29,31)
  • Key:SAGZIBJAQGBRQA-UHFFFAOYSA-N

GW 788388 is a synthetic compound which acts as a potent and selective inhibitor for TGF beta receptor 1.[1] It has applications in research into various disorders such as liver, kidney and heart disease (especially associated with Chagas disease),[2][3][4][5][6][7] and potential antiviral properties.[8]

See also

References

  1. ↑ Gellibert F, de Gouville AC, Woolven J, Mathews N, Nguyen VL, Bertho-Ruault C, et al. (April 2006). "Discovery of 4-{4-[3-(pyridin-2-yl)-1H-pyrazol-4-yl]pyridin-2-yl}-N-(tetrahydro-2H- pyran-4-yl)benzamide (GW788388): a potent, selective, and orally active transforming growth factor-beta type I receptor inhibitor". Journal of Medicinal Chemistry. 49 (7): 2210–2221. doi:10.1021/jm0509905. PMID 16570917.
  2. ↑ de Oliveira FL, Araújo-Jorge TC, de Souza EM, de Oliveira GM, Degrave WM, Feige JJ, et al. (2012). "Oral administration of GW788388, an inhibitor of transforming growth factor beta signaling, prevents heart fibrosis in Chagas disease". PLOS Neglected Tropical Diseases. 6 (6): e1696. doi:10.1371/journal.pntd.0001696. PMC 3373641. PMID 22720109.
  3. ↑ McMillin M, Grant S, Frampton G, Petrescu AD, Williams E, Jefferson B, DeMorrow S (May 2019). "The TGFβ1 Receptor Antagonist GW788388 Reduces JNK Activation and Protects Against Acetaminophen Hepatotoxicity in Mice". Toxicological Sciences. 170 (2): 549–561. doi:10.1093/toxsci/kfz122. PMC 6821297. PMID 31132129.
  4. ↑ Petersen M, Thorikay M, Deckers M, van Dinther M, Grygielko ET, Gellibert F, et al. (March 2008). "Oral administration of GW788388, an inhibitor of TGF-beta type I and II receptor kinases, decreases renal fibrosis". Kidney International. 73 (6): 705–715. doi:10.1038/sj.ki.5002717. PMID 18075500.
  5. ↑ Tan SM, Zhang Y, Connelly KA, Gilbert RE, Kelly DJ (May 2010). "Targeted inhibition of activin receptor-like kinase 5 signaling attenuates cardiac dysfunction following myocardial infarction". American Journal of Physiology. Heart and Circulatory Physiology. 298 (5): H1415–H1425. doi:10.1152/ajpheart.01048.2009. PMID 20154262.
  6. ↑ Ferreira RR, Abreu RD, Vilar-Pereira G, Degrave W, Meuser-Batista M, Ferreira NV, et al. (July 2019). "TGF-β inhibitor therapy decreases fibrosis and stimulates cardiac improvement in a pre-clinical study of chronic Chagas' heart disease". PLOS Neglected Tropical Diseases. 13 (7): e0007602. doi:10.1371/journal.pntd.0007602. PMC 6690554. PMID 31365537.
  7. ↑ Lho Y, Do JY, Heo JY, Kim AY, Kim SW, Kang SH (April 2021). "Effects of TGF-β1 Receptor Inhibitor GW788388 on the Epithelial to Mesenchymal Transition of Peritoneal Mesothelial Cells". International Journal of Molecular Sciences. 22 (9): 4739. doi:10.3390/ijms22094739. PMC 8124410. PMID 33947038.
  8. ↑ Teixeira GS, Andrade AA, Torres LR, Couto-Lima D, Moreira OC, Abreu R, et al. (September 2022). "Suppression of TGF-β/Smad2 signaling by GW788388 enhances DENV-2 clearance in macrophages". Journal of Medical Virology. 94 (9): 4359–4368. doi:10.1002/jmv.27879. PMC 9544077. PMID 35596058. S2CID 250497172.
This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.